{
  "docId": "019de073-ace7-72fb-abe1-daa413db1006",
  "docSlug": "7bdf7da39a85a072a380631ad1d0379d",
  "documentTitle": "Cabaletta Bio | Investor Presentation Deck | 23 slides",
  "authorId": "cabaletta-bio",
  "authorName": "Cabaletta Bio",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 17,
  "pageCount": 23,
  "prevPage": 16,
  "nextPage": 18,
  "slideType": "problem_statement",
  "function": "frame_problem",
  "density": "dense",
  "nDataPoints": 5,
  "notes": "Includes a molecular structure diagram of MuSK and a pie chart of MG patient segments.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de073-ace7-72fb-abe1-daa413db1006/17",
  "deckHref": "/decks/019de073-ace7-72fb-abe1-daa413db1006",
  "deckJsonHref": "/decks/019de073-ace7-72fb-abe1-daa413db1006.json",
  "deckAnchorHref": "/decks/019de073-ace7-72fb-abe1-daa413db1006#slide-17",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.3,
        "x": 0.6,
        "y": 0.3
      },
      "kind": "chart",
      "text": "MuSK MG prevalence breakdown",
      "attrs": null,
      "subkind": "pie",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "77aa852e-cb97-4488-a7f6-b5bc24f7bd0e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.3,
        "x": 0.6,
        "y": 0.75
      },
      "kind": "disclaimer",
      "text": "Total US MG Prevalence: 50,000 to 80,000 patients",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "360b8382-b226-4f98-8367-fccfadc31026",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.15,
        "x": 0.35,
        "y": 0.3
      },
      "kind": "image",
      "text": "MuSK molecular structure diagram",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7618975a-64ab-4632-a8df-e52590e6c16c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.3,
        "x": 0.05,
        "y": 0.4
      },
      "kind": "list",
      "text": "IgG4-dominant disease, similar to PV; Autoantibody titers drop after rituximab; Pathogenic B cells are incompletely eliminated by rituximab and persist during relapse",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5bfdccbd-24f4-435b-9d97-5a614b654e39",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.5,
        "x": 0.05,
        "y": 0.1
      },
      "kind": "paragraph",
      "text": "All known extracellular domains are included in the CAAR design",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2d3b3d5c-56d5-44f9-a4c1-e34501c493ba",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.85
      },
      "kind": "source-note",
      "text": "1. Hain, Berit, et al... 6. Marino, Mariapaola, et al.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4feeade0-cddb-4ecd-9810-39fd3d2033e4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.7,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "High unmet need in MuSK myasthenia gravis; a valuable CAAR target",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "31195b64-d9f8-4923-b349-c5f608222e9e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 17,
      "from": 14,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "5feb5883-6e1a-454b-a089-f5a12b3713b0",
      "evidence": "Problem statement and traction slides",
      "position": 0,
      "objective": "Highlight limitations of current treatments",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}